OncoSenX Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $650K

  • Investors
  • 8

OncoSenX General Information

Description

Developer of transient gene therapies designed to treat cancer with fewer side effects. The company's therapy delivers a program that induces apoptosis in cancerous cells and plasmid DNA delivered with a novel proteo-lipid vehicle that selectively kills cancerous cells based on their transcriptional activity, enabling cancer patients, doctors, and medical care professionals to treat cancer in a precise and less invasive manner.

Contact Information

Website
www.oncosenx.com
Formerly Known As
Oisin Oncology
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 701 Fifth Avenue
  • Suite 4200
  • Seattle, WA 98104
  • United States
+1 (206)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 701 Fifth Avenue
  • Suite 4200
  • Seattle, WA 98104
  • United States
+1 (206)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoSenX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 05-Aug-2021 $650K Completed Pre-Clinical Trials
3. Early Stage VC 30-Apr-2020 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 01-Jan-2020 $30M $30M Completed Pre-Clinical Trials
1. Spin-Off 01-Jan-2018 Completed Startup
To view OncoSenX’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

OncoSenX Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 3

    Pending

  • Expiring in next 12 mo

OncoSenX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4580604-A2 Compositions and methods for in vivo expression of chimeric antigen receptors Pending 02-Sep-2022
EP-4580604-A4 Compositions and methods for in vivo expression of chimeric antigen receptors Pending 02-Sep-2022
US-20260034241-A1 Compositions and methods for in vivo expression of chimeric antigen receptors Pending 02-Sep-2022
WO-2024050551-A2 Compositions and methods for in vivo expression of chimeric antigen receptors Inactive 02-Sep-2022
WO-2024050551-A3 Compositions and methods for in vivo expression of chimeric antigen receptors Inactive 02-Sep-2022 A61K48/0033
To view OncoSenX’s complete patent history, request access »

OncoSenX Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OncoSenX Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Althea Group (New York) Venture Capital Minority
Angel (individual) Minority
Helios Capital (New York) Family Office Minority
Methuselah Foundation Not-For-Profit Venture Capital Minority
Angel (individual) Minority
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

OncoSenX FAQs

  • When was OncoSenX founded?

    OncoSenX was founded in 2017.

  • Where is OncoSenX headquartered?

    OncoSenX is headquartered in Seattle, WA.

  • What is the size of OncoSenX?

    OncoSenX has 9 total employees.

  • What industry is OncoSenX in?

    OncoSenX’s primary industry is Drug Discovery.

  • Is OncoSenX a private or public company?

    OncoSenX is a Private company.

  • What is OncoSenX’s current revenue?

    The current revenue for OncoSenX is .

  • How much funding has OncoSenX raised over time?

    OncoSenX has raised $34.8M.

  • Who are OncoSenX’s investors?

    Althea Group (New York), , Helios Capital (New York), Methuselah Foundation, and are 5 of 8 investors who have invested in OncoSenX.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process